Common Genetic Polymorphisms of Adenosine A2A Receptor do not Influence Response to Regadenoson

Abstract

The common A2A variants studied are not associated with variability in hemodynamic response to regadenoson or variability in detection of ischemia with nuclear perfusion stress imaging.

Cell-type-specific interrogation of CeA Drd2 neurons to identify targets for pharmacological modulation of fear extinction

“…Adora2a was an attractive candidate for further inquiry and was chosen for initial characterization based on a number of reasons: (1) it has previously been shown to almost entirely co-express with Drd2 (Fig. 1g–l ) within the amygdala, and (2) several pharmacological agents targeting ADORA2A are currently in clinical trials or have been approved for use in humans 67 , 68 . The highly selective ADORA2A antagonist, Istradefylline, is selective for ADORA2A over ADORA1 with a Ki of 2.2 and 150 nM, respectively 69 , 70 .…”

Cell-Type Specific Interrogation of CeADrd2Neurons to Identify Targets for Pharmacological Modulation of Fear Extinction

“…Agonists and antagonists targeting ADORA2A, NPY5R, and RXR receptors were chosen from the literature (Figure 5A) 52 . Adora2a was an attractive candidate for further inquiry and was chosen for initial characterization based on a number of reasons; 1) it has previously been shown to almost entirely co-express with Drd2 (Figures 1G-L and 2) within the amygdala, and 2) several pharmacological agents targeting ADORA2A are currently in clinical trials or have been approved for use in humans 53,54 . The highly selective ADORA2A antagonist, istradefylline, is selective for ADORA2A over ADORA1 with a Ki of 2.2 and 150 nM respectively 55,56 .…”